-
Delivered 12% full-year revenue growth despite 2025 being only the third time in 25 years that U.S. injectable volumes declined.
-
Attributed Jeuveau’s 14% market share capture to a ‘beauty-first’ strategy that aligns with cash-pay aesthetic practices rather than reimbursement models.
-
Successfully piloted a new portfolio growth rebate program designed to incentivize accounts to consolidate their toxin and filler spend with Evolus.
-
Expanded the Evolysse HA filler footprint to over 3,000 purchasing accounts, leveraging Cold-X Technology to meet consumer demand for natural-looking results.
-
Executed a structural expense reset in mid-2025 to align the organization for durable, profitable growth and meaningful operating leverage.
-
International revenue nearly doubled year-over-year, driven by a transition to a direct model in Germany and approaching double-digit share in the U.K.
-
Maintained brand resilience through Evolus Rewards, an SMS-based loyalty program that has grown to over 1.4 million treated patients.
-
Projecting 2026 total net revenue between $327 million and $337 million, assuming a low single-digit toxin market recovery and a low single-digit filler market decline.
-
Anticipating full-year 2026 profitability with low to mid-single-digit adjusted EBITDA margins, supported by a largely flat non-GAAP operating expense base.
-
Planning the European launch of Estyme in the second quarter of 2026 and expecting FDA approval of Evolysse Sculpt in the fourth quarter.
-
Initiating a large-scale sampling and experience program for Evolysse in Q2 2026 to broaden adoption ahead of the Sculpt flagship launch.
-
Reiterating 2028 targets of $450 million to $500 million in revenue with 13% to 15% adjusted EBITDA margins as the portfolio scales.
-
Implemented a new revolving credit facility providing up to $40 million in liquidity to fund working capital and inventory for upcoming product launches.
-
Confirmed that Jeuveau is currently unaffected by tariffs, while Evolysse is subject to a 15% tariff assumption in the 2026 guidance.
-
Transitioned the primary profitability metric to adjusted EBITDA starting in 2026 to improve comparability with industry peers.
-
Stated a clear intention to avoid raising equity capital, focusing instead on existing cash reserves and debt tranches to maintain shareholder value.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
